Combination neoadjuvant therapy for HER2-positive stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of four medicines (RC48, adebrelimab, apatinib, and S-1) as a pre-surgery treatment for people with locally advanced stomach cancer that is HER2 positive. The goal is to shrink the tumor before surgery and possibly improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your stomach or gastroesophageal junction cancer is locally advanced (has not spread to distant organs) and can be surgically removed.
- Your tumor tests positive for HER2 (a protein that helps cancer grow) at level 2+ or 3+.
- You have not had any previous chemotherapy or immunotherapy for this cancer.
- You are in good general health (ECOG score 0 or 1) and your major organs work well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This Phase 1/2 study tests RC48-ADC (an antibody-drug treatment) together with S-1 (a chemotherapy medicine) in people with advanced stomach or esophagus/gastroesophageal junction cancer. It’s mainly for cancers with HER2 testing results of IHC 2+ and FISH-negative, and aims to find a safe dose and how well the treatment works as a first treatment option.
This trial tests a combination of three drugs—RC48 (a targeted therapy), sintilimab (an immunotherapy), and S-1 (a chemotherapy pill)—as a first treatment for advanced HER2-positive stomach cancer that has not been treated before. The goal is to see if this triple therapy works better than current options.
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
This trial tests a combination of three drugs after surgery for HER2-positive stomach cancer: an immunotherapy (serplulimab), a targeted therapy (trastuzumab), and chemotherapy (SOX). The goal is to see if this treatment helps prevent the cancer from coming back.
Hear when a new Gastric Cancer/Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.